In lung cancer, GBP1 overexpression, spurred by circular RNA Circ_0058608, drives erlotinib resistance via PGK1-activated epithelial-to-mesenchymal transition (EMT), enabling cells to adopt a mesenchymal, drug-resistant phenotype that evades tyrosine kinase inhibitors, driven by GBP1’s plasma membrane and cytoskeletal localization [64]. This evidence concerns the gene GBP1 and lung cancer.